TL;DR
YME1L1 promotes cancer cell growth, invasion and energy production, while TRIM21 slows these processes, which point to a potential novel strategy for the management of bladder cancer via targeting the TRIM21-YME1L1 pathway.
The findings establish the TRIM2-DTNBP1 axis as a key driver of PCa progression and position TRIM2 as a promising prognostic biomarker and a potential predictive indicator for guiding molecularly targeted therapies in advanced PCa.
Lung adenocarcinoma (LUAD) is one of the major subtypes of non-small cell lung cancer (NSCLC), but the molecular mechanisms underlying LUAD initiation and progression remain incompletely understood. In the present study, we identified TRIM46 as a key driver of LUAD progression. TRIM46 is significantly overexpressed i...
The intrinsic role of LAMP2 in BLCA progression is clarified and MRGPRX4 modulator-2 (Mm-2), a LAMP2-binding small molecule with anti-tumor activity against BLCA, is identified as a candidate LAMP2-targeting agent acting on STING signaling via drug screening and molecular docking.
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, and its molecular pathogenesis remains incompletely understood, with effective therapeutic options still limited. Establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) has been implicated in the development and progression...
EIF2AK2, also known as PKR, is a stress-responsive kinase that regulates multiple cellular processes, including autophagy, apoptosis, and tumor progression. However, the mechanisms underlying EIF2AK2 stability and function in bladder cancer (BLCA) remain underexplored. In this study, we investigated the mechanisms gove...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
